DS-7011a
DS-7011a is a selective inhibitor targeting TLR7. DS-7011a inhibits IL-6 production induced by TLR7 stimulation and related responses in B cells and plasmacytoid dendritic cells. DS-7011a is internalized in a TLR7-dependent manner and accumulates in B cells, various dendritic cell subsets, and monocytes/macrophages. DS-7011a can be used in research related to systemic lupus erythematosus (SLE).
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Species Reactivity
Human
IC50 & Target
[1]|
human TLR7 |
In Vitro
DS-7011a suppresses TLR7-stimulated interleukin-6 production in human peripheral blood mononuclear cells in vitro[1].
DS-7011a (0.1-10 μg/mL; 24 h at 37°C) is internalized in a TLR7-dependent manner in human B cells, pDCs, cDCs, and monocytes, but not in human T cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Gene ID
Accession
Target
TLR7
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Monocyte-derived dendritic cell differentiation
Human monocyte-derived dendritic cells are generated by isolating PBMC-derived monocytes and culturing them with GM-CSF plus IL-4, which produces cells with dendritic-cell antigen-presenting properties, reduced monocyte phenotype, and increased dendritic-cell functional readouts such as antigen uptake, allogeneic T-cell stimulation, and expression of markers including HLA-DR, CD80, CD86, CD83, CD1a, or CD209 depending on protocol and maturation state. The main readout is phenotypic and functional differentiation: immature MoDCs are commonly evaluated by loss or reduction of CD14 with acquisition of dendritic-cell markers and antigen uptake capacity, whereas mature MoDCs are evaluated by increased CD83, CD80, CD86, HLA-DR, and T-cell stimulatory function after exposure to maturation stimuli such as TNF-α or a cytokine/PGE2 cocktail.
Purity & Documentation
References
[1]. Senaldi G, et al. First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of DS-7011a, an Anti-TLR7 Antagonistic Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus. J Clin Pharmacol. Published online August 22, 2024. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
DS-7011a Related Classifications
HY-P992348 Related Classifications
Powered by Bioz